CDT (CDT Equity Inc. Common Stock) Stock Analysis - News
CDT Equity Inc. Common Stock (CDT) is a publicly traded Healthcare sector company. As of May 21, 2026, CDT trades at $1.28 with a market cap of $7.29M and a P/E ratio of -0.00. CDT moved +4.58% today. Year to date, CDT is -96.49%; over the trailing twelve months it is -99.89%. Its 52-week range spans $1.18 to $54,960.00. Rallies surfaces CDT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CDT news today?
CDT Equity Flags Sarborg’s Three-Week Patent Filing for Two CF Compounds: Sarborg filed a new Substance of Matter patent covering two established cystic fibrosis compounds using its Signature Agent and Multi-Agent platform in under three weeks. As a 20% shareholder, CDT Equity will collaborate on combination therapy assessments and expand its IP position.
Nirland Ltd sold 939.01K (~$96.53K) on Oct 7, 2024.
Nirland Ltd sold 1.37M (~$140.46K) on Oct 4, 2024.
Nirland Ltd sold 1.50M (~$156.45K) on Oct 3, 2024.
CDT Analyst Consensus
CDT analyst coverage data. Average price target: $0.00.
Common questions about CDT
What changed in CDT news today?
CDT Equity Flags Sarborg’s Three-Week Patent Filing for Two CF Compounds: Sarborg filed a new Substance of Matter patent covering two established cystic fibrosis compounds using its Signature Agent and Multi-Agent platform in under three weeks. As a 20% shareholder, CDT Equity will collaborate on combination therapy assessments and expand its IP position.
Does Rallies summarize CDT news?
Yes. Rallies summarizes CDT news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CDT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CDT. It does not provide personalized investment advice.
